

08/23/01
JC966 U.S. PTO

08-27-01

A
JC978 U.S. PTO
09/939476
08/23/01

Practitioner's Docket No. 701039-51500 C

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

NEW CONTINUATION APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of
Inventor(s): Evan Y. Snyder, William P. Lynch, Xandra O. Breakefield and Karen Aboody

For (title): ENGRAFTABLE NEURAL PROGENITOR & STEM CELLS FOR BRAIN TUMOR
THERAPY

1. Type of Application

This new application is for a(n)

(check one applicable item below)

- ☐ Original (nonprovisional)
☐ Design
☐ Plant
☐ Divisional.
☒ Continuation.
☐ Continuation-in-part (C-I-P).

2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)

- ☐ The new application being transmitted claims the benefit of prior U.S. application(s).

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) AND 1.10*

(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231.

37 C.F.R. Section 1.8(a)

37 C.F.R. Section 1.10*

- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Address"
Mailing Label No. EL 565096151 US
(mandatory)

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office (703) _____

Date:

8/23/01

Signature

Evan Y. Snyder
(type or print name of person certifying)

Enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE
BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

3. Papers Enclosed

A. Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application

21 Pages of Specification
3 Pages of Claims
3 Sheets of Drawing

B. Other Papers Enclosed

Copies of Power of Attorney by Assignee of Entire Interest (Revocation of Prior Powers) from Prior Application No. 09/168,350;
Copies of Statements Under 37 C.F.R. § 3.73 (b) Establishing Right of Assignee to take action from Prior Application No. 09/168,350;
Copy of 2 month Extension from Prior Application No. 09/168,350.
1 Page of Abstract

4. Additional Papers Enclosed

☐ Amendment to claims

☐ Cancel in this applications claims _____ before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

☐ Add the claims shown on the attached amendment. (Claims added have been numbered consecutively following the highest numbered original claims.)

☐ Preliminary Amendment

☒ Information Disclosure Statement (37 C.F.R. Section 1.98)

☒ Form PTO-1449 (PTO/SB/08A and 08B)

☒ Citations

☐ Declaration of Biological Deposit

☐ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.

☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative

☐ Special Comments

☐ Other

5. Declaration or Oath (including power of attorney)

☒ Enclosed – (Copies of Power of Attorney by Assignee of Entire Interest (Revocation of Prior Powers) from Prior Application No. 09/168,350; and
Copies of Statements Under 37 C.F.R. § 3.73 (b) Establishing Right of Assignee to take action from Prior Application No. 09/168,350)

Executed by

(check all applicable boxes)

- ☐ inventor(s).
☐ legal representative of inventor(s). 37 C.F.R. Section 1.42 or 1.43.
☐ joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.

- ☐ This is the petition required by 37 C.F.R. Section 1.47 and the statement required by 37 C.F.R. Section 1.47 is also attached. See item 13 below for fee.

- ☐ Not Enclosed.

- ☐ Application is made by a person authorized under 37 C.F.R. 1.41 on behalf of *all* the above named inventor(s).

- ☐ Showing that the filing is authorized.
(not required unless called into question. 37 C.F.R. Section 1.41(d))

6. Assignment

- ☒ An assignment of the invention to Northeastern Ohio Universities of Medicine, Children's Medical Center Corporation and The General Hospital Corporation are being filed in Prior Application No. 09/168,350.

WARNING: A newly executed "STATEMENT UNDER 37 C.F.R. Section 3.73(b)" must be filed when a continuation-in-part application is filed by an assignee. Notice of April 30, 1993, 1150 O.G. 62-64.

- ☐ will follow.

7. Fee Calculation (37 C.F.R. Section 1.16)

- A. ☒ Regular application

CLAIMS AS FILED

Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$710.00
Total Claims (37 C.F.R.	Section 1.16(c))	15	- 20 =	0	\$18.00

Independent Claims

(37 C.F.R. Section 3
1.16(b))

- 3 =

0

\$80.00

Multiple Dependent

Claim(s), if any
(37 C.F.R. Section
1.16(d))

+

\$270.00

-
- ☐ Amendment canceling extra claims is enclosed.
☐ Amendment deleting multiple-dependencies is enclosed.
☐ Fee for extra claims is not being paid at this time.

Filing Fee Calculation \$355.00

- B. ☐ Design application
(\$320.00--37 C.F.R. Section 1.16(f))

Filing Fee Calculation \$_____

- C. ☐ Plant application
(\$490.00--37 C.F.R. Section 1.16(g))

Filing Fee Calculation \$_____

8. **Small Entity:** This is a filing by a small entity

9. **Fee Payment Being Made at This Time**

☐ Not Enclosed

☐ No filing fee is to be paid at this time.

(This and the surcharge required by 37 C.F.R. Section 1.16(e) can be paid subsequently.)

☒ Enclosed

☐ Filing fee \$355.00

Total Fees Enclosed \$355.00

10. **Method of Payment of Fees**

☒ Check in the amount of \$355.00.

☐ Charge Account No. _____ in the amount of \$_____.
A duplicate of this transmittal is attached.

11. **Authorization to Charge Additional Fees**

☒ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 50-0850.

☒ 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)

☒ 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)

70230-927650

[illegible]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Snyder et al.

Group No.:

Application No.: To be assigned

Examiner:

Filed: Herewith

For: ENGRAFTABLE NEURAL PROGENITOR AND STEM CELLS FOR BRAIN TUMOR THERAPY

Box Patent Application

Assistant Commissioner for Patents

Washington, D.C. 20231

EXPRESS MAIL CERTIFICATE

"Express Mail" label number: EL 565096151 US


Date of Deposit: 23 August 2001

I hereby state that the following *attached* papers and fee

1. Continuation Application (specification – 21 pp.; claims – 3 pp.; abstract – 1 p.);
2. 3 pages of drawings;
3. Continuation Application Transmittal (6 pp.);
4. Preliminary Amendment (2 pp.)
5. Copy of Extension of Time from Parent Application (2 pp.);
6. Copies of Power of Attorney by Assignee of Entire Interest (Revocation of Prior Powers) and Statements Under 37 C.F.R. 3.73 from parent application;
7. Information Disclosure Statement and Form 1449 (3 pp.);
8. References AA-AC and CA-CF;
9. Check in the amount of \$355.00; and
10. Return Receipt postcard.

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the date indicated above and is addressed to the Box Provisional Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Zinna L. Mang


Signature of person mailing paper or fee